

ASX ANNOUNCEMENT

Analytica raises \$1,532m. \$1.045M from exercise of unlisted Options and \$487k from placement.

12 June 2018 - Analytica Ltd (ASX:ALT) is pleased to announce the raising of an additional \$1.045M of capital from shareholders exercising unlisted options which expired 31 May 2018.

This tranche of options resulted in a total of 208,922,920 options (\$1.045k) being exercised from a potential 265,839,671 options issued, a 78.6% participation rate.

The options were issued as part of the renounceable pro-rata entitlement offer announced on 18 September 2017. Under the Entitlement Offer, for every share subscribed the Company issued 1 option exercisable at \$0.005 on or before 31 January 2018; and 1 option exercisable at \$0.005 on or before 31 May 2018. This capital strategy was put in place to facilitate sufficient cash to meet then current and future requirements.

The first tranche of options which expired on 31 January 2018 resulted in a total of 183,713,441 options (\$919k) being exercised from a potential 265,839,671 options issued, a 69.1% participation rate.

Analytica has also issued private placements to sophisticated investors at the same exercise price of the unlisted options of \$0.005, raising a further \$487k (97,400,000 ordinary shares).

This capital strengthens Analytica's cash position to pursue the goals of building best in class, proving the PeriCoach works and partnering with a multinational to commercialise. The support of shareholders is appreciated.

Shares will be allotted on the 13 June 2018.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland.

